Designing Microbicides Against HIV: Innovative Rings for Young Women Urgently Needed

Jespers, Vicky; Noëstlinger, Christiana; Ariën, Kevin K.

doi:10.2217/fvl-2016-0135

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fate of the DPV ring continued in a clinical study known as MTN-023/IPM 030. It was designed to provide the kind of information about safety and tolerability of DPV VR that regulatory authorities would need to expand the approval of the ring to include its use also for girls under the age of 18 (58). The study was a multi-center, two-arm, randomized, double-blind, placebo-controlled phase IIa clinical trial.…”

Section: Clinical Testing Of Dapivirine Vaginal Preparationsmentioning

confidence: 99%

Clinical testing of antiretroviral drugs as future prevention against vaginal and rectal transmission of HIV infection – a review of currently available results

et al. 2019

View full text Add to dashboard Cite

The original purpose of vaginally applied microbicides was to slow down the HIV epidemic among the population until an effective vaccination was developed. Nowadays, antiretrovirals applied in the form of gels or vaginal rings are considered most prominent in this field and are tested via vaginal or, rarely, rectal applications in numerous clinical studies (9 different antiretroviral drugs in 33 clinical studies, especially in Africa). Only tenofovir (1 % gel) and dapivirine (25 mg in vaginal ring) progressed into the phase III clinical testing. Their efficiency depended on the user´s strict adherence to the application regimen (for tenofovir 54 %, for dapivirine 61 % in participants over 25 years of age). Despite this, they are expected to be important and effective tools of preventive medicine in the near future. This review summarizes the results obtained during long-term clinical testing (2005–2018) of antiretroviral drugs against vaginal and rectal transmission of HIV infection.

show abstract

Section: Clinical Testing Of Dapivirine Vaginal Preparationsmentioning

confidence: 99%